Last reviewed · How we verify
Silymarine supplementation
Silymarin is a flavonolignan extract from milk thistle that acts as a hepatoprotective agent by reducing oxidative stress and supporting liver cell regeneration.
Silymarin is a flavonolignan extract from milk thistle that acts as a hepatoprotective agent by reducing oxidative stress and supporting liver cell regeneration. Used for Liver disease support and hepatoprotection, Drug-induced liver injury prevention or treatment.
At a glance
| Generic name | Silymarine supplementation |
|---|---|
| Sponsor | University Hospital, Martin |
| Drug class | Herbal supplement / Hepatoprotective agent |
| Modality | Small molecule |
| Therapeutic area | Hepatology / Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Silymarin contains active compounds (primarily silibinin) that function as antioxidants and anti-inflammatory agents, protecting hepatocytes from toxin-induced damage and enhancing detoxification pathways. It stabilizes cell membranes, inhibits lipid peroxidation, and may promote protein synthesis and liver cell regeneration. The mechanism is thought to involve free radical scavenging and modulation of inflammatory signaling pathways.
Approved indications
- Liver disease support and hepatoprotection
- Drug-induced liver injury prevention or treatment
Common side effects
- Gastrointestinal disturbance
- Allergic reaction (rare)
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Silymarine supplementation CI brief — competitive landscape report
- Silymarine supplementation updates RSS · CI watch RSS
- University Hospital, Martin portfolio CI